Study: Aspirin effective in preventing clots following joint replacement surgery
PHILADELPHIA – Recent research from the Rothman Institute at Jefferson has shown aspirin to be just as effective in preventing clots — specifically pulmonary emboli, life-threatening blood clots that can develop in the arteries of the lungs following joint replacement surgery — Thomas Jefferson University announced Wednesday.
“While warfarin is successful in the prophylactic prevention of clots it can also lead to increased bleeding, infections and hospital readmissions,” stated Javad Parvizi, director of Research at the Rothman Institute and lead author on the study.
The study compared the outcomes of 26,415 patients who underwent joint replacement surgery at the Rothman Institute between 2000 and 2011; 1,824 of whom received aspirin and 24,567 of whom received warfarin prophylactically prior to surgery. Both groups were monitored for up to 90 days postoperatively.
Their results showed the overall rate of pulmonary embolism to be significantly lower in the patients who received aspirin (0.2% or four in 1,824) versus those who received warfarin (1% or 92 in 9028). In addition, hematoma, a leakage of blood external to the blood vessel or a leakage of fluid known as a seroma, wound problems, acute infection and 90-day mortality rates were also lower in the aspirin group.
“Our study shows that aspirin is a viable alternative to warfarin in healthy patients, with better results in preventing clots, and a lower rate of bleeding and wound complications,” Parvizi said. “It will allow all us to move away from expensive, inconvenient and dangerous drugs in the prevention of thromboembolism after joint replacement.”
Rothman Institute at Jefferson surgeons have begun to replace warfarin with aspirin for pre-surgical prophylactic clot prevention, he added.
Very interesting article. Wondering if there have been studies done comparing aspirin to enoxaparin for prevention of thromboembolism after joint replacement surgery and what the results are. Thank you for bringing this to our attention!
GSK awards $200,000 in grants to nonprofit healthcare organizations reaching underserved communities
RESEARCH TRIANGLE PARK, N.C. — GlaxoSmithKline on Thursday announced the five recipients of its annual GlaxoSmithKline IMPACT Awards. In total, the North Carolina and Philadelphia-area healthcare nonprofit organizations will receive $200,000 in grant funding ($40,000 each) for providing access to healthcare for the underserved in their communities.
"The GlaxoSmithKline IMPACT Award winners are helping to make their communities stronger and healthier," stated Mary Linda Andrews, director of community partnerships, GSK. "The dedicated teams of professionals and volunteers at these organizations are working in innovative ways to provide access to healthcare at a time when people need it most."
The following organizations will receive their awards at a ceremony on Dec. 11 in Research Triangle Park:
- Piedmont Health Services and Sickle Cell Agency, Greensboro, N.C.
- Restoration Place Ministries, Greensboro, N.C.
- The Servant Center, Greensboro, N.C.
- Triad Health Project, Greensboro, N.C.
- Institute for Safe Families, Philadelphia
In North Carolina, GSK works in partnership with Durham-based Triangle Community Foundation, a grant-making organization that connects resources with needs through community-based philanthropy.
"Millions of Americans fall between the gaps and are not receiving the most basic healthcare services," stated Lori O’Keefe, COO at TCF. "Our partnership with GSK celebrates and supports groups that are filling those gaps and creating hope for thousands of members of our communities."
The GlaxoSmithKline IMPACT Awards — which stands for Innovation, Management, Partnership, Achievement, Community focus and Targeting needs of diverse and underserved populations — honor nonprofit organizations that have a significant impact on their communities and are capable, proactive and effective in their work.
To qualify for a GlaxoSmithKline IMPACT award, organizations must be located in the eligible counties and have a primary mission to provide access to community healthcare services. Each applicant must have annual total operating expenses between $160,000 and $3 million, and have been in existence as a 501(c)(3) nonprofit organization for at least five years.
All organizations are recognized for the success and achievements of their existing overall body of work, not just for new or specific initiatives. A panel of healthcare delivery experts and GlaxoSmithKline representatives determine the winners based on a strong demonstration of ongoing success in providing access to healthcare, commitment to serving people in need, facilitation of healthcare delivery, creative partnerships and policy development, and a solid record of achievement, management and leadership.
No comments found
C&D to initiate trial of its Trojan Vibrations line across several urban markets
PRINCETON, N.J. — Church & Dwight will be initiating trial of its Trojan Vibrations personal massagers with a multi-city giveaway, the company announced Wednesday. Beginning in Washington on Nov. 13, Church & Dwight will feature its latest product innovations via a specially-designed Trojan Vibrations Pleasure Carts that are modeled after traditional hot dog carts.
"With the success of the Trojan vibrator giveaway in New York City, it is evident that Americans understand that pleasure is a normal part of sexually healthy lives," stated Bruce Weiss, VP marketing, Trojan sexual health. "By innovating high-quality vibrators and making them easily accessible on drug store, mass merchandiser and grocery store shelves, Trojan remains dedicated to taking pleasure out of the bedroom and into the mainstream."
People can track the tour and uncover upcoming stops by visiting Facebook.com/TrojanVibrations.
No comments found